Study of QL0911 for low platelets caused by chemo
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called QL0911 to help raise platelet counts in people with cancer whose chemo has caused low platelets. The goal is to see if it can prevent delays in treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed cancer diagnosis and are on a 21-day chemotherapy cycle.
- You have experienced low platelet counts (thrombocytopenia) that delayed your chemo.
- You are able to do most of your daily activities (ECOG 0 or 1).
- You do not have a history of bleeding problems or other blood disorders besides those caused by chemo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for children with a condition called immune thrombocytopenia (ITP), which causes low blood platelets and easy bruising or bleeding. It may help increase platelet counts when standard treatments haven't worked.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
This trial tests a new combination of two medicines (hetrombopag and rhTPO) that help raise platelet counts, which often drop during cancer treatment. The goal is to see if this approach works well and is safe for people with low platelets caused by cancer therapy.
This trial tests a combination of two new drugs (QLS31905 and/or QL1706) with chemotherapy for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can shrink tumors and help people live longer.
Hear when a new Cancer Treatment-Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.